Re: Zenith Abstract at AACR 2017 Meeting April 1-5

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Abstract at AACR 2017 Meeting April 1-5

in response to

Re: Zenith Abstract at AACR 2017 Meeting April 1-5

tada

posted on Apr 03, 2017 01:38PM

Tada,

That is a poster from last year's AACR meeting focusing on the pre-clinical characterization of ZEN-3694. Figure 2 and 5 that you mention are in mouse xenograft models dosed with ZEN-3694. My comment "I think all we've seen so far is gene modulation 24 hours after administration of the lowest dose" referred to human dosing. Zenith collaborated with Eva Corey and Holly Nguyen from Univ. of Washington to do one of the xenograft models.